Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets
NEW YORK, June 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Markets for Enzyme Inhibitors -- Focus on Emerging Marketshttp://www.reportlinker.com/p0919322/Global-Markets-for-Enzyme-Inhibitors----Focus-on-Emerging-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
REPORT SCOPE
INTRODUCTION STUDY GOALS AND OBJECTIVESThe overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.
This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.
A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.
Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THE STUDYResearch and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE SCOPE OF REPORT India China Japan Taiwan Canada Africa Australia New Zealand METHODOLOGY AND INFORMATION SOURCESMany companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.
ANALYST CREDENTIALS
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.
The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on "Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.)," which was given an award of excellence.
TABLE OF CONTENTSCHAPTER 1
INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE 1
SCOPE OF REPORT 2
METHODOLOGY AND INFORMATION SOURCES 2
ANALYST CREDENTIALS 2
RELATED REPORTS 2
BCC ON-LINE SERVICES 3
DISCLAIMER 3
CHAPTER 2
SUMMARY 5
SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($
MILLIONS) 6
SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016 ($
MILLIONS) 6
CHAPTER 3 OVERVIEW 8
DEFINITIONS 8
STRUCTURE OF ENZYMES 8
ACTIVATION ENERGY 8
SPECIFICITY 8
ENZYME SUBSTRATE INTERACTION 9
CONDITIONS OF ENZYME ACTION 9
CLASSIFICATION OF ENZYMES 9
OXIDOREDUCTASES 10
TRANSFERASES 10
HYDROLASES 10
NUCLEASES 11
PHOSPHATASES 11
LYASES 11
ISOMERASES 11
LIGASES 11
REAL-LIFE APPLICATIONS OF ENZYMES 11
METABOLIC ENZYMES 12
DIGESTIVE ENZYMES 13
FOOD ENZYMES 14
NEED FOR ENZYMES IN HUMAN BODY 14
PROTEOLYTIC ENZYMES 14
LIPOLYTIC ENZYMES 15
AMYLOLYTIC ENZYMES 15
RENNIN ENZYMES 15
WHAT ARE ENZYME INHIBITORS 15
WHY ENZYME INHIBITION 15
USE OF ENZYME INHIBITORS 16
MECHANISM OF ENZYME INHIBITION 16
TYPES OF ENZYME INHIBITORS 16
MIXED INHIBITION 17
COMPETITIVE INHIBITION 17
CLASSIFICATION OF ENZYME INHIBITORS 17
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17
OXIDOREDUCTASE INHIBITORS 18
ALDOSE REDUCTASE INHIBITORS 18
STATINS 19
HISTORY OF DEVELOPMENT OF STATINS 19
TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19
5-ALPHA-REDUCTASE INHIBITORS 19
AROMATASE INHIBITORS 20
COX-2 INHIBITORS 20
HYDROLASE INHIBITORS 20
NEURAMINIDASE INHIBITORS 20
PROTEASE INHIBITORS 21
TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 22
PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS 22
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 22
TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23
PROTON PUMP INHIBITORS 23
TRANSFERASE INHIBITORS 23
PROTEIN KINASE INHIBITORS 23
REVERSE TRANSCRIPTASE INHIBITORS 24
CHAPTER 4 REGULATORY ASPECTS 26
TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26
TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29
TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30
CHAPTER 5
MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS 34
TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34
TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34
TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35
TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35
TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36
TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE
INHIBITORS 36
TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37
TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 38
TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38
CHAPTER 6
NEW DEVELOPMENTS 41
TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41
TABLE 18 CLINICAL TRIALS OF STATINS 42
TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 44
TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 45
TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 47
TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51
TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52
TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 52
TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 54
TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 54
NEW DRUGS IN CLINICAL TRIALS 55
TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 55
CHAPTER 7
GLOBAL MARKETS 58
MARKET ANALYSIS 58
TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 59
FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 59
PROTON PUMP INHIBITORS 60
MARKET OVERVIEW 60
MARKET REVENUE 61
TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 61
FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 62
PROTEASE INHIBITORS 62
MARKET OVERVIEW 62
MARKET REVENUE 63
TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 63
FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 64
REVERSE TRANSCRIPTASE INHIBITORS 64
MARKET OVERVIEW 65
MARKET REVENUE 66
TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 66
FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 66
KINASE INHIBITORS 67
MARKET OVERVIEW 67
MARKET REVENUE 69
TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69
FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69
STATINS 70
MARKET OVERVIEW 71
MARKET REVENUE 72
TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 72
FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 72
AROMATASE INHIBITORS 73
MARKET OVERVIEW 73
MARKET REVENUE 74
TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 74
FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 74
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 75
MARKET OVERVIEW 75
MARKET REVENUE 76
TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 76
FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 76
NEURAMINIDASE INHIBITORS 77
MARKET OVERVIEW 77
MARKET REVENUE 78
TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 78
FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 78
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 79
MARKET OVERVIEW 80
MARKET REVENUE 80
TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 80
FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 81
MARKET SHARES 81
TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81
FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81
TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87
FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87
MARKET BY APPLICATIONS 87
TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE
SECTORS, THROUGH 2016 ($ MILLIONS) 88
FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/
DISEASE SECTORS, 2009-2016 ($ MILLIONS) 88
CARDIOVASCULAR (CV) DISEASE 89
TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
THROUGH 2016 ($ MILLIONS) 90
FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
2009-2016 ($ MILLIONS) 90
GASTROINTESTINAL DISORDERS 91
TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
THROUGH 2016 ($ MILLIONS) 92
FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
2009-2016 ($ MILLIONS) 92
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 93
TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($
MILLIONS) 94
FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 94
HEPATITIS 94
TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($
MILLIONS) 95
FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($
MILLIONS) 95
CANCER 96
TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH
2016 ($ MILLIONS) 98
FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 ($
MILLIONS) 98
ERECTILE DYSFUNCTION (ED) 99
TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
THROUGH 2016 ($ MILLIONS) 100
FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
2009-2016 ($ MILLIONS) 100
OTHERS 100
TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016
($ MILLIONS) 101
FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($
MILLIONS) 101
GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION 102
TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) 102
FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%) 102
CHAPTER 8 EMERGING MARKETS 105
MARKET ANALYSIS 105
TABLE 56 EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 106
FIGURE 29 EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 106
PROTON PUMP INHIBITORS 107
MARKET OVERVIEW 107
MARKET REVENUE 108
TABLE 57 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($
MILLIONS) 108
FIGURE 30 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 108
PROTEASE INHIBITORS 109
MARKET OVERVIEW 109
MARKET REVENUE 109
TABLE 58 EMERGING MARKETS FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 109
FIGURE 31 EMERGING MARKETS FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 110
REVERSE TRANSCRIPTASE INHIBITORS 110
MARKET OVERVIEW 110
MARKET REVENUE 111
TABLE 59 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 112
FIGURE 32 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 112
KINASE INHIBITORS 112
MARKET OVERVIEW 113
MARKET REVENUE 114
TABLE 60 EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 114
FIGURE 33 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 114
STATINS 114
MARKET OVERVIEW 115
MARKET REVENUE 116
TABLE 61 EMERGING MARKETS FOR STATINS, THROUGH 2016 ($ MILLIONS) 116
FIGURE 34 EMERGING MARKETS FOR STATINS, 2009-2016 ($ MILLIONS) 116
AROMATASE INHIBITORS 116
MARKET OVERVIEW 117
MARKET REVENUE 117
TABLE 62 EMERGING MARKETS FOR AROMATASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 117
FIGURE 35 EMERGING MARKETS FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 117
PDE5 INHIBITORS 118
MARKET OVERVIEW 118
MARKET REVENUE 118
TABLE 63 EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 119
FIGURE 36 EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 119
NEURAMINIDASE INHIBITORS 119
MARKET OVERVIEW 119
MARKET REVENUE 120
TABLE 64 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($
MILLIONS) 120
FIGURE 37 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($
MILLIONS) 120
ACE INHIBITORS 121
MARKET OVERVIEW 121
MARKET REVENUE 121
TABLE 65 EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 121
FIGURE 38 EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 122
MARKET SHARES OF INDUSTRY LEADERS IN EMERGING MARKETS 122
PROTON PUMP INHIBITORS 122
TABLE 66 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,
2010 (%) 122
FIGURE 39 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,
2010 (%) 122
PROTEASE INHIBITORS 123
TABLE 67 EMERGING MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010
(%) 123
FIGURE 40 EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS,
2010 (%) 123
KINASE INHIBITORS 124
TABLE 68 EMERGING MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%) 124
FIGURE 41 EMERGING MARKET SHARES OF KINASE INHIBITORS MANUACTURERS, 2010 (%) 124
STATINS 125
TABLE 69 EMERGING MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 125
FIGURE 42 EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010 (%) 125
AROMATASE INHIBITORS 126
TABLE 70 EMERGING MARKET SHARES OF AROMATASE INHIBITOR, 2010 (%) 126
FIGURE 43 EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS,
2010 (%) 126
REVERSE TRANSCRIPTASE INHIBITORS 127
TABLE 71 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR
MANUFACTURERS, 2010 (%) 127
FIGURE 44 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS,
2010 (%) 127
PDE5 INHIBITORS 128
TABLE 72 EMERGING MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 128
FIGURE 45 EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010 (%) 128
NEURAMINIDASE INHIBITORS 129
TABLE 73 EMERGING MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS,
2010 (%) 129
FIGURE 46 EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%) 129
ACE INHIBITORS 130
TABLE 74 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130
FIGURE 47 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130
MARKET BY APPLICATIONS 130
TABLE 75 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC
CATEGORIES/DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 131
FIGURE 48 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC
CATEGORIES/DISEASE SECTORS ($ MILLIONS) 131
CARDIOVASCULAR (CV) DISEASE 132
TABLE 76 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES,
THROUGH 2016 ($ MILLIONS) 134
FIGURE 49 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES,
2009-2016 ($ MILLIONS) 134
GASTROINTESTINAL DISORDERS 134
TABLE 77 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES,
THROUGH 2016 ($ MILLIONS) 135
FIGURE 50 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL
DISEASES, 2009-2016 ($ MILLIONS) 135
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 135
TABLE 78 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($
MILLIONS) 136
FIGURE 51 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($
MILLIONS) 136
HEPATITIS 137
TABLE 79 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($
MILLIONS) 138
FIGURE 52 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($
MILLIONS) 138
CANCER 139
TABLE 80 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH
2016 ($ MILLIONS) 140
FIGURE 53 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS,
2009-2016 ($ MILLIONS) 140
ERECTILE DYSFUNCTION (ED) 140
TABLE 81 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
THROUGH 2016 ($ MILLIONS) 141
FIGURE 54 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
2009-2016 ($ MILLIONS) 141
OTHER DISEASES 141
TABLE 82 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH
2016 ($ MILLIONS) 142
FIGURE 55 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016
($ MILLIONS) 142
CHAPTER 9 PATENT ANALYSIS 144
PATENTS BY YEAR 144
TABLE 83 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012 144
FIGURE 56 NUMBER OF PATENTS BY YEAR, 2008-2012 144
FIGURE 57 NUMBER OF PATENTS BY YEAR, 2008-2012 (%) 145
PATENTS BY TYPE 145
TABLE 84 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012 146
FIGURE 58 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012 146
PATENTS BY COMPANY 147
TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012 147
PATENTS BY COUNTRY 148
TABLE 86 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008-2012 148
FIGURE 59 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008–2012 149
TABLE 87 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008-2012 (%) 150
FIGURE 60 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012 (%) 150
PATENTS BY ASSIGNEE 150
TABLE 88 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012 151
FIGURE 61 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 151
CHAPTER 10 CURRENT SITUATION 153
MARKET CONDITIONS 153
UNITED STATES 153
EUROPE 153
EMERGING MARKETS 153
TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET 154
COMPETITION 154
PATENT EXPIRATIONS 154
UPCOMING PATENT EXPIRATIONS/UPCOMING PATENT CLIFF 154
PATENT CHALLENGES / LEGAL PROCEEDINGS 154
NEW INDICATIONS APPROVED 155
NEW DRUG APPROVALS 155
RX- TO- OTC SWITCH 156
INCREASING NUMBER OF BABY BOOMERS 156
MERGERS AND ACQUISITIONS AND ALLIANCES 156
DIRECT-TO-CONSUMER ADVERTISING 157
CHAPTER 11 COMPANY PROFILES 159
ABBOTT LABORATORIES 159
AMGEN INC. 159
ASTRAZENECA PLC 159
AUROBINDO PHARMA 160
BAYER HEALTHCARE PHARMACEUTICALS 160
BOEHRINGER INGELHEIM GMBH 161
BRISTOL-MYERS SQUIBB 161
CIPLA LTD. 162
DR. REDDY'S LABORATORIES LTD. 162
EISAI INC. 163
ELI LILLY & CO. 163
ENDO PHARMACEUTICALS 164
GILEAD SCIENCES INC. 164
GLAXOSMITHKLINE PLC 164
GLENMARK GENERICS LTD. 165
HETERO DRUGS LTD. 165
HOFFMAN-LA ROCHE LTD. 166
INCYTE CORP. 166
JOHNSON & JOHNSON 167
LUPIN PHARMACEUTICALS INC. 167
MERCK & CO. INC. 168
MERCK SERONO SA 168
MYLAN LABORATORIES INC. 169
MYLAN LABORATORIES LTD. 169
NOVARTIS AG 170
OSI PHARMACEUTICALS LLC 170
PAR PHARMACEUTICAL COMPANIES INC. 171
PFIZER INC. 171
RANBAXY LABORATORIES LTD. 172
ROXANE LABORATORIES LTD. 172
SANDOZ 173
SANOFI-AVENTIS 173
SANTARUS INC. 174
SUN PHARMACEUTICALS 174
TAKEDA PHARMACEUTICAL CO. LTD. 175
TEVA PHARMACEUTICAL INDUSTRIES LTD. 175
VERTEX PHARMACEUTICALS 175
VIIV HEALTHCARE 176
WATSON PHARMACEUTICALS INC. 176
CHAPTER 12 APPENDIX—ABBREVIATIONS 179
LIST OF TABLESTABLE HEADING PAGE NO. SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($ MILLIONS) 6 TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17 TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19 TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21 TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23 TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26 TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29 TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30 TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34 TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34 TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35 TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35 TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36 TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS 36 TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37 TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 38 TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38 TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41 TABLE 18 CLINICAL TRIALS OF STATINS 42 TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 44 TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 45 TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 47 TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51 TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52 TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 52 TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 54 TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 54 TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 55 TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 59 TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 61 TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 63 TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 66 TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69 TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 72 TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 74 TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 76 TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 78 TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 80 TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81 TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82 TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83 TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83 TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84 TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85 TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85 TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86 TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87 TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 88 TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016 ($ MILLIONS) 90 TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016 ($ MILLIONS) 92 TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($ MILLIONS) 94 TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($ MILLIONS) 95 TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016 ($ MILLIONS) 98 TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 100 TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016 ($ MILLIONS) 101 TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) 102 TABLE 56 EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 106 TABLE 57 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 108 TABLE 58 EMERGING MARKETS FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 109 TABLE 59 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 112 TABLE 60 EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 114 TABLE 61 EMERGING MARKETS FOR STATINS, THROUGH 2016 ($ MILLIONS) 116 TABLE 62 EMERGING MARKETS FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 117 TABLE 63 EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 119 TABLE 64 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 120 TABLE 65 EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 121 TABLE 66 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010 (%) 122 TABLE 67 EMERGING MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010 (%) 123 TABLE 68 EMERGING MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%) 124 TABLE 69 EMERGING MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 125 TABLE 70 EMERGING MARKET SHARES OF AROMATASE INHIBITOR, 2010 (%) 126 TABLE 71 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010 (%) 127 TABLE 72 EMERGING MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 128 TABLE 73 EMERGING MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010 (%) 129 TABLE 74 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130 TABLE 75 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 131 TABLE 76 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES, THROUGH 2016 ($ MILLIONS) 134 TABLE 77 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES, THROUGH 2016 ($ MILLIONS) 135 TABLE 78 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($ MILLIONS) 136 TABLE 79 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($ MILLIONS) 138 TABLE 80 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016 ($ MILLIONS) 140 TABLE 81 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 141 TABLE 82 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH 2016 ($ MILLIONS) 142 TABLE 83 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012 144 TABLE 84 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012 146 TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012 147 TABLE 86 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008-2012 148 TABLE 87 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008-2012 (%) 150 TABLE 88 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012 151
LIST OF FIGURES
SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016 ($
MILLIONS) 6
FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 59
FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 62
FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 64
FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 66
FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69
FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 72
FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 74
FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 76
FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 78
FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 81
FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81
FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82
FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83
FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84
FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85
FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86
FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87
FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE
SECTORS, 2009-2016 ($ MILLIONS) 88
FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,
2009-2016 ($ MILLIONS) 90
FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,
2009-2016 ($ MILLIONS) 92
FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 94
FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($ MILLIONS) 95
FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 ($
MILLIONS) 98
FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
2009-2016 ($ MILLIONS) 100
FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($
MILLIONS) 101
FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%) 102
FIGURE 29 EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 106
FIGURE 30 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 108
FIGURE 31 EMERGING MARKETS FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 110
FIGURE 32 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($
MILLIONS) 112
FIGURE 33 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 114
FIGURE 34 EMERGING MARKETS FOR STATINS, 2009-2016 ($ MILLIONS) 116
FIGURE 35 EMERGING MARKETS FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 117
FIGURE 36 EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 119
FIGURE 37 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 120
FIGURE 38 EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 122
FIGURE 39 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,
2010 (%) 122
FIGURE 40 EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS,
2010 (%) 123
FIGURE 41 EMERGING MARKET SHARES OF KINASE INHIBITORS MANUACTURERS, 2010 (%) 124
FIGURE 42 EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010 (%) 125
FIGURE 43 EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS,
2010 (%) 126
FIGURE 44 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS,
2010 (%) 127
FIGURE 45 EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010 (%) 128
FIGURE 46 EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%) 129
FIGURE 47 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130
FIGURE 48 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC
CATEGORIES/DISEASE SECTORS ($ MILLIONS) 131
FIGURE 49 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES,
2009-2016 ($ MILLIONS) 134
FIGURE 50 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES,
2009-2016 ($ MILLIONS) 135
FIGURE 51 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($
MILLIONS) 136
FIGURE 52 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($
MILLIONS) 138
FIGURE 53 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016
($ MILLIONS) 140
FIGURE 54 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,
2009-2016 ($ MILLIONS) 141
FIGURE 55 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016
($ MILLIONS) 142
FIGURE 56 NUMBER OF PATENTS BY YEAR, 2008-2012 144
FIGURE 57 NUMBER OF PATENTS BY YEAR, 2008-2012 (%) 145
FIGURE 58 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012 146
FIGURE 59 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,
2008–2012 149
FIGURE 60 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012 (%) 150
FIGURE 61 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 151
To order this report:Drug and Medication Industry: Global Markets for Enzyme Inhibitors -- Focus on Emerging MarketsMore
Market Research ReportCheck our
Industry Analysis and InsightsContact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article